Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jade Ghosn

Showing results (91-100 of 267) with videos related to

Pageof 27
Sort By:
Antimicrobial Agents and Chemotherapy|February 5, 2014
Population pharmacokinetics of emtricitabine in HIV-1-infected adult patientsElodie Valade, Jean-Marc Tréluyer, Naïm Bouazza, et al.
The Journal of Antimicrobial Chemotherapy|February 20, 2010
Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohortJade Ghosn, Christiane Deveau, Marie-Laure Chaix, et al.
AIDS Research and Human Retroviruses|June 22, 2010
Short communication: evidence of HIV type 1 complex and second generation recombinant strains among patients infected in 1997-2007 in France: ANRS CO06 PRIMO CohortJulie Galimand, Pierre Frange, Christine Rouzioux, et al.
The Journal of Antimicrobial Chemotherapy|May 28, 2020
Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case reportJuliette Kauv, Minh P Lê, Marc Veyrier, et al.
AIDS (London, England)|June 15, 2012
Boosted protease inhibitor monotherapy as a maintenance strategy: an observational studyMarguerite Guiguet, Jade Ghosn, Claudine Duvivier, et al.
AIDS (London, England)|January 25, 2003
Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patientsJade Ghosn, Claire Lamotte, Hocine Ait-Mohand, et al.
HIV Medicine|July 5, 2026
Mpox clinical outcomes among people living with HIV and PrEP users: Findings from the MASH-1 multicentre cohort studyNicolo Girometti, Andrew Hill, Bryony Simmons, et al.
The Journal of Antimicrobial Chemotherapy|August 9, 2011
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapyJuliette Pavie, Raphael Porcher, Carlo Torti, et al.
Plos One|November 13, 2015
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In VitroLucie Fénéant, Jade Ghosn, Baptiste Fouquet, et al.
AIDS (London, England)|September 27, 2005
No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patientsJade Ghosn, Marc Wirden, Nadine Ktorza, et al.
Pageof 27

Showing results (91-100 of 267) with videos related to

Sort By:
Pageof 27
Antimicrobial Agents and Chemotherapy|February 5, 2014
Population pharmacokinetics of emtricitabine in HIV-1-infected adult patientsElodie Valade, Jean-Marc Tréluyer, Naïm Bouazza, et al.
The Journal of Antimicrobial Chemotherapy|February 20, 2010
Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohortJade Ghosn, Christiane Deveau, Marie-Laure Chaix, et al.
AIDS Research and Human Retroviruses|June 22, 2010
Short communication: evidence of HIV type 1 complex and second generation recombinant strains among patients infected in 1997-2007 in France: ANRS CO06 PRIMO CohortJulie Galimand, Pierre Frange, Christine Rouzioux, et al.
The Journal of Antimicrobial Chemotherapy|May 28, 2020
Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case reportJuliette Kauv, Minh P Lê, Marc Veyrier, et al.
AIDS (London, England)|June 15, 2012
Boosted protease inhibitor monotherapy as a maintenance strategy: an observational studyMarguerite Guiguet, Jade Ghosn, Claudine Duvivier, et al.
AIDS (London, England)|January 25, 2003
Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patientsJade Ghosn, Claire Lamotte, Hocine Ait-Mohand, et al.
HIV Medicine|July 5, 2026
Mpox clinical outcomes among people living with HIV and PrEP users: Findings from the MASH-1 multicentre cohort studyNicolo Girometti, Andrew Hill, Bryony Simmons, et al.
The Journal of Antimicrobial Chemotherapy|August 9, 2011
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapyJuliette Pavie, Raphael Porcher, Carlo Torti, et al.
Plos One|November 13, 2015
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In VitroLucie Fénéant, Jade Ghosn, Baptiste Fouquet, et al.
AIDS (London, England)|September 27, 2005
No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patientsJade Ghosn, Marc Wirden, Nadine Ktorza, et al.
Pageof 27